Neurocrine Biosciences
NBIX
#1301
Rank
A$24.80 B
Marketcap
A$246.72
Share price
1.24%
Change (1 day)
22.17%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$9.99

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$9.57. In 2025 the company made an earnings per share (EPS) of A$6.87 an increase over its 2024 EPS that were of A$4.82.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$9.9945.4%
2025A$6.8742.6%
2024A$4.8233.07%
2023A$3.6257.76%
2022A$2.3069.47%
2021A$1.35-78.21%
2020A$6.22990%
2019A$0.5781.82%
2018A$0.31-113.5%
2017A-$2.320.62%
2016A-$2.3157.28%
2015A-$1.4725.61%
2014A-$1.1718.84%
2013A-$0.98-1085.71%
2012A$0.09983

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.87-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.93-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$40.25 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.31-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.89-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$4.99-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$42.64-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.72-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK